Legend Biotech Corporation
LEGN
$32.80
-$0.66-1.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 120.97% | -588.73% | 69.57% | 58.71% | -132.80% |
| Total Depreciation and Amortization | 27.76% | 3.10% | 3.43% | -1.23% | 4.82% |
| Total Amortization of Deferred Charges | -34.39% | -14.21% | -58.64% | 94.93% | -9.02% |
| Total Other Non-Cash Items | -157.12% | 32,597.88% | 99.48% | -167.78% | 4,420.46% |
| Change in Net Operating Assets | -360.37% | -253.05% | -89.30% | 1,138.68% | -299.34% |
| Cash from Operations | -8.25% | -4,492.49% | -110.64% | 116.22% | -57.19% |
| Capital Expenditure | -15.16% | 39.57% | 45.28% | -43.73% | 19.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -125.81% | 147.84% | -77.53% | -194.67% | 302.19% |
| Cash from Investing | -126.69% | 147.31% | -75.60% | -197.21% | 294.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 19.59% | -0.34% | -53.03% | -349.34% | 117.66% |
| Issuance of Common Stock | -88.85% | 155.74% | 33.10% | 155.88% | -76.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -107.84% | 344.50% | 14.92% | -10.16% | -3.75% |
| Foreign Exchange rate Adjustments | -534.16% | 5,722.22% | 102.62% | -123.59% | 285.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.87% | 137.06% | -83.17% | -220.97% | 216.50% |